These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34130872)

  • 21. Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
    Valerio M; Emberton M; Ahmed HU
    Eur Urol; 2019 Feb; 75(2):e21-e22. PubMed ID: 30224194
    [No Abstract]   [Full Text] [Related]  

  • 22. Re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 2013;63:450-8.
    Kim KH; Rha KH
    Eur Urol; 2013 Sep; 64(3):e55-6. PubMed ID: 23746720
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.
    Kim J; Park JS; Ham WS
    Investig Clin Urol; 2017 Sep; 58(5):307-316. PubMed ID: 28868501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: Sanoj Punnen, Matthew R. Cooperberg, Anthony V. D'Amico, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.025: Re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
    Parker C; Sydes MR; Kynaston H;
    Eur Urol; 2013 Nov; 64(5):e102. PubMed ID: 23953599
    [No Abstract]   [Full Text] [Related]  

  • 25. Re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.06.057.
    van der Poel HG; Buckle T; Valdes Olmos R
    Eur Urol; 2013 Feb; 63(2):e20. PubMed ID: 23153744
    [No Abstract]   [Full Text] [Related]  

  • 26. Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.
    Fanti S; Krause B; Weber W; Castellucci P; Grosu AL; de Jong IJ; Messa C; Picchio M; Pruim J; Langsteger W; Chiti A;
    Eur Urol; 2011 Nov; 60(5):e37-8; author reply e39-41. PubMed ID: 21855205
    [No Abstract]   [Full Text] [Related]  

  • 27. Reply to Kwang Hyun Kim and Koon Ho Rha's letter to the editor Re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 2013;63:450-8.
    Tosco L; Van den Bergh L; Joniau S
    Eur Urol; 2013 Sep; 64(3):e57-8. PubMed ID: 23769590
    [No Abstract]   [Full Text] [Related]  

  • 28. Re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8: Future Steps for Definitive Therapy in Metastatic Prostate Cancer: Lessons from the HORRAD Trial.
    Shinde A; Li R; Amini A; Glaser S
    Eur Urol; 2019 Mar; 75(3):e69-e70. PubMed ID: 30463663
    [No Abstract]   [Full Text] [Related]  

  • 29. Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Moris L; Mottet N; Wiegel T
    Eur Urol; 2020 Sep; 78(3):e116-e117. PubMed ID: 32536484
    [No Abstract]   [Full Text] [Related]  

  • 30. Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Moris L; Van den Broeck T; Wiegel T;
    Eur Urol; 2020 Sep; 78(3):e120-e121. PubMed ID: 32684306
    [No Abstract]   [Full Text] [Related]  

  • 31. Re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8.
    Gregucci F; Fiorentino A
    Eur Urol; 2019 May; 75(5):e129-e130. PubMed ID: 30591351
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80.
    Montorsi F; Scuderi S; Briganti A; Gandaglia G
    Eur Urol; 2023 May; 83(5):e132. PubMed ID: 36774224
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol 2022;81:407-13.
    Montorsi F; Stabile A; Mazzone E; Gandaglia G; Briganti A
    Eur Urol; 2022 Sep; 82(3):e73. PubMed ID: 35661628
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77: 508-47 https://doi.org/10.1016/j.eururo.2020.01.012.
    von Eyben FE; Bauman G; Soydal C; Paganelli G
    Eur Urol; 2020 Nov; 78(5):e201-e202. PubMed ID: 32222292
    [No Abstract]   [Full Text] [Related]  

  • 35. Re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8: High-volume Disease Has a Different Standard of Care.
    García-Perdomo HA
    Eur Urol; 2019 Apr; 75(4):e100. PubMed ID: 30477982
    [No Abstract]   [Full Text] [Related]  

  • 36. Reply from Authors re: Roderick C.N. van den Bergh, Declan G. Murphy, Henk G. van der Poel. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. Eur Urol 2016;70:767-8.
    Godtman RA; Stranne J; Hugosson J
    Eur Urol; 2016 Nov; 70(5):769-770. PubMed ID: 27210462
    [No Abstract]   [Full Text] [Related]  

  • 37. Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8.
    Vis AN; Boevé LMS
    Eur Urol; 2019 May; 75(5):e131-e132. PubMed ID: 30616950
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9 and re: John Anderson. Androgen-deprivation therapy--It's all a matter of timing. Eur Urol 2008;53:869-71.
    Kirollos MM
    Eur Urol; 2009 Feb; 55(2):e40-2; author reply e45-6. PubMed ID: 18760526
    [No Abstract]   [Full Text] [Related]  

  • 39. Reply to Henk G. van der Poel, Tessa Buckle and Renato Valdes Olmos' letter to the editor re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.06.057.
    Joniau S; Van den Bergh L
    Eur Urol; 2013 Feb; 63(2):e21-2. PubMed ID: 23149147
    [No Abstract]   [Full Text] [Related]  

  • 40. Re: Hashim U. Ahmed, Louise Dickinson, Susan Charman, et al. Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. Eur Urol 2015;68:927-36.
    Li H; Yan W; Ji Z
    Eur Urol; 2016 Nov; 70(5):e131. PubMed ID: 27085626
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.